An international consensus list of potentially clinically significant drug-drug interactions in older people

P Anrys; A-E Petit; S  Thevelin; B.  Sallevelt; C.  Drenth; Roy Soiza; Andrea Correa-Pérez; O.  Dalleur; I.  De Brauwer; Mirko  Petrovic; J.J.  Coleman; K. Dalton; Denis  O’Mahony; J Löwe; S Thürig; A.  Gudmundsson; A Cherubin; Agapios  Panos; Dimitris Mavridis; N Rodondi; A.  Spinewine

doi:10.1016/j.jamda.2021.03.019

An international consensus list of potentially clinically significant drug-drug interactions in older people

P Anrys, A-E Petit, S Thevelin, B. Sallevelt, C. Drenth, Roy Soiza, Andrea Correa-Pérez, O. Dalleur, I. De Brauwer, Mirko Petrovic, J.J. Coleman, K. Dalton, Denis O’Mahony, J Löwe, S Thürig, A. Gudmundsson, A Cherubin, Agapios Panos, Dimitris Mavridis, N RodondiA. Spinewine^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Objectives: We aimed to establish an explicit list of potentially clinically significant DDIs in people aged ≥65 years.
Design: A preliminary list of potentially clinically significant DDIs was compiled, based on 154 DDIs identified from literature review. Subsequently, a two-round online Delphi survey was undertaken with a multidisciplinary expert panel. A consensus meeting and a final round were conducted to validate the final DDI list and the scope of information provided.
Setting and Participants: 29 experts, including geriatricians and clinical pharmacists from eight European countries
Measures: For each DDI, in the first two rounds, experts were asked to score the severity of potential harm on a five-point Likert scale. DDIs were directly included on the final list if the median score was 4 (major) or 5 (catastrophic). DDIs with a median score of 3 (moderate) were discussed at a consensus meeting and included if ≥75% of participants voted for inclusion in the final round.
Results: Consensus was achieved on 66 potentially clinically significant DDIs (28 had a median score of 4/5 and 48 of 3 in the Delphi survey). Most concerned cardiovascular, antithrombotic, and central nervous system drugs. The final list includes information on the mechanism of interaction, harm, and management. Treatment modification is recommended for three-quarters of DDIs.
Conclusion and implications: We validated a list of potentially clinically significant DDIs in older people, which can be used in clinical practice and education to support identification and management of DDIs or to assess prevalence in epidemiological and intervention studies

Original language	English
Pages (from-to)	2121-2133.e24
Number of pages	37
Journal	Journal of the American Medical Directors Association
Volume	22
Issue number	10
Early online date	24 Apr 2021
DOIs	https://doi.org/10.1016/j.jamda.2021.03.019
Publication status	Published - 31 Oct 2021

Keywords

Delphi Technique
Drug Interaction
Aged

Access to Document

10.1016/j.jamda.2021.03.019Licence: Unspecified

Anrys_et_al_JAMDA_AnInternationalConsensusList_AAM
© 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 3.69 MBLicence: CC BY-NC-ND

Cite this

Anrys, P., Petit, A-E., Thevelin, S., Sallevelt, B., Drenth, C., Soiza, R., Correa-Pérez, A., Dalleur, O., De Brauwer, I., Petrovic, M., Coleman, J. J., Dalton, K., O’Mahony, D., Löwe, J., Thürig, S., Gudmundsson, A., Cherubin, A., Panos, A., Mavridis, D., ... Spinewine, A. (2021). An international consensus list of potentially clinically significant drug-drug interactions in older people. Journal of the American Medical Directors Association, 22(10), 2121-2133.e24. https://doi.org/10.1016/j.jamda.2021.03.019

Anrys, P, Petit, A-E, Thevelin, S, Sallevelt, B, Drenth, C, Soiza, R, Correa-Pérez, A, Dalleur, O, De Brauwer, I, Petrovic, M, Coleman, JJ, Dalton, K, O’Mahony, D, Löwe, J, Thürig, S, Gudmundsson, A, Cherubin, A, Panos, A, Mavridis, D, Rodondi, N & Spinewine, A 2021, 'An international consensus list of potentially clinically significant drug-drug interactions in older people', Journal of the American Medical Directors Association, vol. 22, no. 10, pp. 2121-2133.e24. https://doi.org/10.1016/j.jamda.2021.03.019

@article{24742999ab0845b883036c188e8bde5c,

title = "An international consensus list of potentially clinically significant drug-drug interactions in older people",

abstract = "Objectives: We aimed to establish an explicit list of potentially clinically significant DDIs in people aged ≥65 years. Design: A preliminary list of potentially clinically significant DDIs was compiled, based on 154 DDIs identified from literature review. Subsequently, a two-round online Delphi survey was undertaken with a multidisciplinary expert panel. A consensus meeting and a final round were conducted to validate the final DDI list and the scope of information provided.Setting and Participants: 29 experts, including geriatricians and clinical pharmacists from eight European countries Measures: For each DDI, in the first two rounds, experts were asked to score the severity of potential harm on a five-point Likert scale. DDIs were directly included on the final list if the median score was 4 (major) or 5 (catastrophic). DDIs with a median score of 3 (moderate) were discussed at a consensus meeting and included if ≥75% of participants voted for inclusion in the final round.Results: Consensus was achieved on 66 potentially clinically significant DDIs (28 had a median score of 4/5 and 48 of 3 in the Delphi survey). Most concerned cardiovascular, antithrombotic, and central nervous system drugs. The final list includes information on the mechanism of interaction, harm, and management. Treatment modification is recommended for three-quarters of DDIs.Conclusion and implications: We validated a list of potentially clinically significant DDIs in older people, which can be used in clinical practice and education to support identification and management of DDIs or to assess prevalence in epidemiological and intervention studies",

keywords = "Delphi Technique, Drug Interaction, Aged",

author = "P Anrys and A-E Petit and S Thevelin and B. Sallevelt and C. Drenth and Roy Soiza and Andrea Correa-P{\'e}rez and O. Dalleur and {De Brauwer}, I. and Mirko Petrovic and J.J. Coleman and K. Dalton and Denis O{\textquoteright}Mahony and J L{\"o}we and S Th{\"u}rig and A. Gudmundsson and A Cherubin and Agapios Panos and Dimitris Mavridis and N Rodondi and A. Spinewine",

note = "ACKNOWLEDGEMENTS We gratefully acknowledge the valuable input of the expert panel in the validation of the DDI list (members of the expert panel who are not co-authors of the manuscript were: Benoit Boland, Stephen Byrne, Alessandro Caraffa, Samanta Corradi, Manuel Velez Diaz-Pallares, Anne Fournier, Petur Gunnarsson, Lianne Huibers, Anna Ingibjorg Gunnarsdottir, Joan MacLeod, Paolo Marinelli, Beatriz Montero Errasquin, Olafur Samuelsson, Annemie Somers, Ingeborg Wilting). We thank Perrine Evrard, Catherine P{\'e}tein and Simon Lion for their support in developing the final drug-drug interaction tables and the coding with ATC codes. We thank Anne-Laure Sennesael for her support in the literature review on drug-drug interactions with direct oral anticoagulants.",

year = "2021",

month = oct,

day = "31",

doi = "10.1016/j.jamda.2021.03.019",

language = "English",

volume = "22",

pages = "2121--2133.e24",

journal = "Journal of the American Medical Directors Association",

issn = "1525-8610",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - An international consensus list of potentially clinically significant drug-drug interactions in older people

AU - Anrys, P

AU - Petit, A-E

AU - Thevelin, S

AU - Sallevelt, B.

AU - Drenth, C.

AU - Soiza, Roy

AU - Correa-Pérez, Andrea

AU - Dalleur, O.

AU - De Brauwer, I.

AU - Petrovic, Mirko

AU - Coleman, J.J.

AU - Dalton, K.

AU - O’Mahony, Denis

AU - Löwe, J

AU - Thürig, S

AU - Gudmundsson, A.

AU - Cherubin, A

AU - Panos, Agapios

AU - Mavridis, Dimitris

AU - Rodondi, N

AU - Spinewine, A.

N1 - ACKNOWLEDGEMENTS We gratefully acknowledge the valuable input of the expert panel in the validation of the DDI list (members of the expert panel who are not co-authors of the manuscript were: Benoit Boland, Stephen Byrne, Alessandro Caraffa, Samanta Corradi, Manuel Velez Diaz-Pallares, Anne Fournier, Petur Gunnarsson, Lianne Huibers, Anna Ingibjorg Gunnarsdottir, Joan MacLeod, Paolo Marinelli, Beatriz Montero Errasquin, Olafur Samuelsson, Annemie Somers, Ingeborg Wilting). We thank Perrine Evrard, Catherine Pétein and Simon Lion for their support in developing the final drug-drug interaction tables and the coding with ATC codes. We thank Anne-Laure Sennesael for her support in the literature review on drug-drug interactions with direct oral anticoagulants.

PY - 2021/10/31

Y1 - 2021/10/31

N2 - Objectives: We aimed to establish an explicit list of potentially clinically significant DDIs in people aged ≥65 years. Design: A preliminary list of potentially clinically significant DDIs was compiled, based on 154 DDIs identified from literature review. Subsequently, a two-round online Delphi survey was undertaken with a multidisciplinary expert panel. A consensus meeting and a final round were conducted to validate the final DDI list and the scope of information provided.Setting and Participants: 29 experts, including geriatricians and clinical pharmacists from eight European countries Measures: For each DDI, in the first two rounds, experts were asked to score the severity of potential harm on a five-point Likert scale. DDIs were directly included on the final list if the median score was 4 (major) or 5 (catastrophic). DDIs with a median score of 3 (moderate) were discussed at a consensus meeting and included if ≥75% of participants voted for inclusion in the final round.Results: Consensus was achieved on 66 potentially clinically significant DDIs (28 had a median score of 4/5 and 48 of 3 in the Delphi survey). Most concerned cardiovascular, antithrombotic, and central nervous system drugs. The final list includes information on the mechanism of interaction, harm, and management. Treatment modification is recommended for three-quarters of DDIs.Conclusion and implications: We validated a list of potentially clinically significant DDIs in older people, which can be used in clinical practice and education to support identification and management of DDIs or to assess prevalence in epidemiological and intervention studies

AB - Objectives: We aimed to establish an explicit list of potentially clinically significant DDIs in people aged ≥65 years. Design: A preliminary list of potentially clinically significant DDIs was compiled, based on 154 DDIs identified from literature review. Subsequently, a two-round online Delphi survey was undertaken with a multidisciplinary expert panel. A consensus meeting and a final round were conducted to validate the final DDI list and the scope of information provided.Setting and Participants: 29 experts, including geriatricians and clinical pharmacists from eight European countries Measures: For each DDI, in the first two rounds, experts were asked to score the severity of potential harm on a five-point Likert scale. DDIs were directly included on the final list if the median score was 4 (major) or 5 (catastrophic). DDIs with a median score of 3 (moderate) were discussed at a consensus meeting and included if ≥75% of participants voted for inclusion in the final round.Results: Consensus was achieved on 66 potentially clinically significant DDIs (28 had a median score of 4/5 and 48 of 3 in the Delphi survey). Most concerned cardiovascular, antithrombotic, and central nervous system drugs. The final list includes information on the mechanism of interaction, harm, and management. Treatment modification is recommended for three-quarters of DDIs.Conclusion and implications: We validated a list of potentially clinically significant DDIs in older people, which can be used in clinical practice and education to support identification and management of DDIs or to assess prevalence in epidemiological and intervention studies

KW - Delphi Technique

KW - Drug Interaction

KW - Aged

U2 - 10.1016/j.jamda.2021.03.019

DO - 10.1016/j.jamda.2021.03.019

M3 - Article

C2 - 33901428

VL - 22

SP - 2121-2133.e24

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 10

ER -

An international consensus list of potentially clinically significant drug-drug interactions in older people

Abstract

Keywords

Access to Document

Fingerprint

Cite this